From November 11–14, ASCO delegates participated in the American Medical Association’s (AMA) Interim Meeting of the House of Delegates (HOD), the principal policy-making body of the AMA. During the meeting, several ASCO-backed resolutions were approved, including:
Medicare Part B Drugs in QPP/MIPS Payment Adjustment
Elimination of the Laboratory 14-Day Rule Under Medicare
Transparency of Pharmacy Benefit Managers
ASCO also co-led a resolution urging the AMA to actively lobby Congress and the federal government to expedite the development of an equitable, validated risk adjustment mechanism and not include a cost score in MIPS until such time as it can be developed. The resolution was referred to the AMA Board of Trustees for decision, and ASCO will continue to elevate the issue within the AMA and through advocacy efforts.
The HOD also discussed other issues relevant to cancer care, including e-prescribing controlled substances, sequestration, MACRA implementation, health disparities, and drug shortages, among others.
ASCO currently sends two delegates to the AMA HOD: Edward P. Balaban, DO, FACP, FASCO, and Thomas Marsland, MD, FASCO. The Society also has two HOD alternate delegates: Ray Page, DO, PhD, FACOI, and Kristina Novick, MD. The society’s Resident and Fellow Section Delegate is Steve Y. Lee, MD.
Stay connected to ASCO’s advocacy activities through ASCO in Action (asco.org/asco-in-action). ■
© 2017. American Society of Clinical Oncology. All rights reserved